PATIENT INFORMATION SHEET – TUMOUR SAMPLE SCREENING

Study Title: A single arm phase II trial of trastuzumab deruxtecan in patients with gastrooesophageal adenocarcinoma cancer who are ctDNA and HER2 positive (DECIPHER)

Chief Investigator: Dr Elizabeth Smyth
Sponsor Reference: 68838
IRAS: 1006810

Request for permission to review your tumour sample

As you will have been told by your doctors, you have been diagnosed with gastrooesophageal adenocarcinoma. Your doctor will explain that you will have neoadjuvant chemotherapy (anti-cancer drugs prior to surgery) to remove your cancer. You may be eligible for a clinical trial called DECIPHER after you have had your surgery. The trial is looking for people who are both HER2 (human epidermal growth factor receptor 2) and ctDNA (circulating tumour DNA) positive. To find out if you are HER2 positive we would like permission for the sample of your diagnostic tissue to be analysed in your local hospital pathology department, no additional biopsy will be required. This may have already been done as standard at your treating NHS hospital. If you are HER2 positive we will then need to see if you are ctDNA positive. We would like your permission to send a sample of your tumour, which will be removed during your standard of care surgery (called a resection tissue sample), and two samples of your blood to the Natera laboratory for analysis. One of these blood samples may be taken prior to your surgery, this will depend on when your HER2 result is available. The other will be taken at a minimum of 4 weeks after your surgery once you are discharged. These blood tests will determine whether you are ctDNA positive or negative.

The resection tissue will be checked by the hospital pathology department to ensure that there is enough of the tumour present to perform the ctDNA testing. In cases where there is not enough of the tumour present in the resection tissue sample, we would like your permission to send your original diagnostic tissue sample to Natera for ctDNA testing.

You do not need to decide if you wish to take part in the trial at this point. If you do decide to take part in the trial, then your doctor will discuss this further with you.

What is the purpose of this review?

We would like you to consider taking part in a clinical research study (a clinical trial called DECIPHER). The aim of this trial is to determine the activity and safety of the immunotherapy drug trastuzumab deruxtecan. The

likelihood and time to your disease coming back (disease recurrence) will be measured. In order to be eligible for the study, we need to confirm that you are HER2 positive and ctDNA positive. If it is found that you are HER2 or ctDNA negative, you will not be invited to take part in the study and your doctors will discuss with you the best alternative therapy.

What does HER2 positive mean?

HER2 positive describes cells that have a protein called HER2 on their surface. In normal cells, HER2 helps control cell growth. Cancer cells that make too much HER2 may grow more quickly and are more likely to spread to other parts of the body.

What does ctDNA positive mean?

Circulating tumour DNA (ctDNA) is found in the bloodstream. It refers to DNA that derives from cancerous cells and tumours. If you are found to be ctDNA positive it means that there are microscopic traces of tumour in your bloodstream. These would not show up on imaging as they are too small to detect.

Do I have to my tumour sample reviewed?

No. You can choose not to have your sample reviewed but it would mean that you cannot consider participation in the DECIPHER study. Your doctors will discuss alternative treatment options with you.

What will happen if I do agree to have my tumour sample reviewed?

If you agree to this review, then we will ask you to sign a consent form. The original consent form will be filed securely at the hospital. A copy of the consent form will be kept in your medical notes, a copy provided to you and a copy will be sent to the Southampton Clinical Trials Unit (SCTU), who are managing this study, via secure email and held securely. A sample of your tumour will be taken out of storage in your local pathology department and analysed for HER2 at your local hospital, if this has not already been performed as part of standard care. Following surgery, a sample of the tumour removed will be sent to the laboratories of Natera and the University of Oxford, or in the cases where there is not enough tumour in the resection sample, the diagnostic tissue sample will be sent. Natera is a clinical laboratory based in the USA, who are specialised in ctDNA testing.

The review will remain strictly confidential at all times. Representatives of regulatory authorities, the trial sponsor and authorised NHS staff may need to review documentation to check that the review of your tumour is being carried out correctly. All of them have a duty of confidentiality to you as a research participant. Nothing that could reveal your identity will be disclosed outside of the research team.

A decision not to consent to have your tumour block reviewed will not affect the quality of care that you receive.

CT scan – your treating doctor may suggest that you have a CT scan before the ctDNA test. This is to make sure that, if you need further treatment, it is not delayed.

Does agreeing to the test mean that I have to take part in the DECIPHER study?

No. You may decide that you do not wish to take part in the DECIPHER clinical trial, in which case your doctors will discuss with you the best alternative therapy. If you decide not to participate in the DECIPHER study, the laboratory will return your tumour sample to your local hospital.

Will my details be kept confidential?

Yes. Your participation and the information we collect about you will be kept strictly confidential. University of Southampton is the sponsor for the DECIPHER study and are based in the United Kingdom. The sponsor and the Southampton Clinical Trials Unit (SCTU), who are acting on behalf of the sponsor, will act as the data controller for this study. This means that the sponsor and SCTU are responsible for ensuring that the procedures outlined with the Patient Information Sheet are adhered to.

You can find out more about how we use your information at https://www.southampton.ac.uk/ctu/about/index.page.

For HER2 analysis, tissue that was taken to diagnose your cancer will be analysed in your local hospital. Staff will adhere to normal NHS confidentiality rules. The results will be added to your patient hospital record.

Individuals who work at the Natera and University of Oxford will see your NHS number as this might be sent along with the tumour samples that you give during your time on the trial for analysis. A copy of your pathology report (with full name removed and replaced with initials and trial identifier) will be sent with the biopsy. All samples will be labelled with your trial identifier and year of birth. Your details would be stored electronically by the Laboratories of Natera and University of Oxford along with your future tumour sample results, should you be eligible and decide to participate in DECIPHER, on their secure NHS servers. The paper copies of your NHS number are destroyed as confidential waste at the end of the trial. Samples sent to Natera will either be destroyed or returned to your local hospital, according to the agreement with your treating hospital. Samples sent to the University of Oxford will be retained for future ethically approved research, if you provide your consent for this.

Your clinician's research team will collect information from you and your medical records for this research study in accordance with our instructions. Only members of the research team at your NHS Trust and responsible members of the University of Southampton may be given access to data about you for monitoring purposes and/or to carry out an audit of the study to ensure that the research is complying with applicable regulations. Individuals from regulatory authorities (people who check that we are carrying out the study correctly) may look at your medical and research records to check the accuracy of the research study. All of these people have a duty to keep your information strictly confidential.

Your NHS Trust will keep identifiable information about you from this study for 25 years after the study has finished. If you choose to participate in the DECIPHER study, your tumour sample may be used in future ethically approved projects.

How do I find out more about DECIPHER?

Your doctor will discuss the DECIPHER clinical trial with you and what the alternatives are. You will have also received a patient information sheet which gives full details of what the study involves. You will have time to ask any questions that you may have.

Additional Information

We would like to encourage you to ask questions about the study until you are clear about what we intend to do. If you have more questions about the tumour quantity review or the DECIPHER study, please contact the DECIPHER Team at decipher@soton.ac.uk.

Thank you for taking the time to read this information sheet.